Literature DB >> 12538423

C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study.

Mary S Beattie1, Michael G Shlipak, Haiying Liu, Warren S Browner, Nelson B Schiller, Mary A Whooley.   

Abstract

BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with an increased risk of coronary events, but whether inflammation is associated with inducible ischemia in patients with stable coronary disease is unknown. METHODS AND
RESULTS: We recruited patients with known coronary disease from 2 VA Medical Centers and 1 University-based medical center for the Heart and Soul Study. We measured CRP levels in 118 participants who had exercise-induced ischemia and in 111 who did not have inducible ischemia, as determined by stress echocardiography. We used logistic regression to examine the risk of exercise-induced ischemia associated with elevated CRP. We found that 75% (39/52) of participants in the highest CRP category (>0.38 mg/dL) had inducible ischemia, compared with 45% (79/177) in the lower 4 categories combined (adjusted odds ratio 4.2; 95% confidence interval 1.6 to 11; P=0.004). However, this association differed in users and nonusers of beta-blockers and statins. Among 89 participants who did not use beta-blockers, 93% in the highest CRP category had exercise-induced ischemia, compared with 42% in the lower 4 categories (P=0.03). Among 67 participants who did not use statins, 94% in the highest CRP category had exercise-induced ischemia, compared with 44% in the lower 4 categories (P=0.009). We did not observe a significant association between CRP and ischemia among participants who were treated with either of these medications.
CONCLUSION: Elevated CRP levels are associated with inducible ischemia in patients with stable coronary disease, particularly among those not treated with beta-blockers or statins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538423      PMCID: PMC2776690          DOI: 10.1161/01.cir.0000044387.23578.e9

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

1.  What is C-reactive protein telling us about coronary artery disease?

Authors:  Stanley S Levinson; Ronald J Elin
Journal:  Arch Intern Med       Date:  2002-02-25

2.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

3.  C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina.

Authors:  James S Zebrack; Joseph B Muhlestein; Benjamin D Horne; Jeffrey L Anderson
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

4.  Angiographic progression of coronary artery disease and the development of myocardial infarction.

Authors:  J A Ambrose; M A Tannenbaum; D Alexopoulos; C E Hjemdahl-Monsen; J Leavy; M Weiss; S Borrico; R Gorlin; V Fuster
Journal:  J Am Coll Cardiol       Date:  1988-07       Impact factor: 24.094

5.  Association between myeloperoxidase levels and risk of coronary artery disease.

Authors:  R Zhang; M L Brennan; X Fu; R J Aviles; G L Pearce; M S Penn; E J Topol; D L Sprecher; S L Hazen
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

6.  Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein.

Authors:  Elisabetta Rossi; Luigi M Biasucci; Franco Citterio; Simona Pelliccioni; Claudia Monaco; Francesca Ginnetti; Dominick J Angiolillo; Gianni Grieco; Giovanna Liuzzo; Attilio Maseri
Journal:  Circulation       Date:  2002-02-19       Impact factor: 29.690

Review 7.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

8.  Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.

Authors:  J A Spertus; J A Winder; T A Dewhurst; R A Deyo; J Prodzinski; M McDonell; S D Fihn
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

9.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial.

Authors:  L H Kuller; R P Tracy; J Shaten; E N Meilahn
Journal:  Am J Epidemiol       Date:  1996-09-15       Impact factor: 4.897

10.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

Authors:  G Liuzzo; L M Biasucci; J R Gallimore; R L Grillo; A G Rebuzzi; M B Pepys; A Maseri
Journal:  N Engl J Med       Date:  1994-08-18       Impact factor: 91.245

View more
  22 in total

1.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

2.  Depression, stress, and quality of life in persons with chronic kidney disease: the Heart and Soul Study.

Authors:  Michelle C Odden; Mary A Whooley; Michael G Shlipak
Journal:  Nephron Clin Pract       Date:  2005-12-07

3.  Lifetime exposure to traumatic psychological stress is associated with elevated inflammation in the Heart and Soul Study.

Authors:  Aoife O'Donovan; Thomas C Neylan; Thomas Metzler; Beth E Cohen
Journal:  Brain Behav Immun       Date:  2012-02-15       Impact factor: 7.217

4.  Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study.

Authors:  Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley
Journal:  Nephrol Dial Transplant       Date:  2006-04-27       Impact factor: 5.992

5.  Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Glenn M Chertow; Sadia Ali; Nelson B Schiller; Mary A Whooley
Journal:  J Card Fail       Date:  2006-10       Impact factor: 5.712

6.  Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Glenn M Chertow; Mary A Whooley
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

7.  Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Vincent M Brandenburg; Sadia Ali; Markus Ketteler; Mary A Whooley
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

Review 8.  Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs.

Authors:  Natália António; Rosa Fernandes; Noela Rodriguez-Losada; Manuel F Jiménez-Navarro; Artur Paiva; Eduardo de Teresa Galván; Lino Gonçalves; Carlos Fontes Ribeiro; Luís A Providência
Journal:  Eur J Clin Pharmacol       Date:  2009-12-10       Impact factor: 2.953

9.  C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study.

Authors:  Eric S Williams; Sanjiv J Shah; Sadia Ali; Bee Ya Na; Nelson B Schiller; Mary A Whooley
Journal:  Eur J Heart Fail       Date:  2007-12-21       Impact factor: 15.534

10.  Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study.

Authors:  Joachim H Ix; Michael G Shlipak; Haiying H Liu; Nelson B Schiller; Mary A Whooley
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.